In this interview, Michael Schwenkert (Bio-Rad Laboratories) describes the challenges for development of CAR-T cell therapies that can be addressed using anti-idiotypic antibodies.
Webinar Q&A follow up – Development of neutralizing antibody assays to support clinical safety assessment: when is a cell-based assay required and what challenges can you expect?
Thank you everyone who attended our live webinar “Development of neutralizing antibody assays to support…
Webinar available to view on demand. Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant?
Poster: novel approach to immunogenicity testing for therapeutics with high prevalence of pre-existing antibodies
Developing Immunogenicity methods for patient populations with a high prevalence of pre-existing antibodies pose challenges that are difficult to validate. Care must be taken to acknowledge these risks during development of screening strategy and method development. In this case study, the therapeutic consisted of two domains (X-Y) in which domain X has homology to a childhood vaccine with known immunogenicity in ≥90% of the U.S. population. Screening strategy includes domain specificity testing using inhibition by excess of each domain for confirmatory cut point determination.
Development of neutralizing antibody assays to support clinical safety assessment: when is a cell-based assay required and what challenges can you expect?
Webinar available on demand. Join our webinar to learn about the critical parameters related to the development of cell-based assays, the expected challenges and how binding assays could potentially be an acceptable replacement.
Read time: 3:45 mins
Find out more about the immunogenicity of antibody–drug conjugates (ADCs) in this column from Corinna Fiorotti, Business Development Director at BioAgilytix (NC, USA).